Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

AbbVie (NY: ABBV )

192.82 +1.07 (+0.56%)
Streaming Delayed Price Updated: 10:56 AM EST, Feb 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
74 75 Next >
Could CVS Make a Copy of Ozempic?
Given its new biosimilars unit, copying Ozempic is more likely than it sounds. 
Via The Motley Fool
3 No-Brainer Dividend Stocks to Buy in September
Income investors should really like these biopharma stocks with juicy dividends. 
Via The Motley Fool
8 Pharma Stocks Affected by New Drug Price Negotiation Rules
Which companies have the most to lose now that Medicare can negotiate directly with them on the prices of some of the most widely used drugs? 
Via The Motley Fool
CVS Just Made a Major New Announcement, But Should You Buy It?
Spinning up a new division will probably be a boon for shareholders. 
Via The Motley Fool
$1000 Invested In AbbVie 10 Years Ago Would Be Worth This Much Today
Via Benzinga
The 3 Most Promising Biotech Stocks to Own Now
These top biotech stock picks with high and leading growth potential are must-owns for investors looking for high upside potential. 
Via InvestorPlace
Looking Into AbbVie's Recent Short Interest
Via Benzinga
This Is What Whales Are Betting On AbbVie
Via Benzinga
1 High-Yield Dividend Stock That Looks Like a Screaming Buy
Look beyond the company's near-term headwinds. 
Via The Motley Fool
Medicare Will Soon Negotiate Some Drug Prices. Is This a Threat to Johnson & Johnson's Earnings?
The healthcare giant's immunology drug Stelara brought in more than $9 billion in revenue last year. 
Via The Motley Fool
A Significant Reversal is in Sight for These 5 Med Tech Companies
Med tech stocks are down YOY despite strong secular tailwinds, cash flow, and dividends; the downturn in action is an opportunity and reversal is at hand. 
Via MarketBeat
What Impact Will Medicare Price Negotiations Have on Big Pharma Stocks?
Investors appear to be yawning for the most part at the latest news on Medicare drug price negotiations. 
Via The Motley Fool
Now or Never: 7 Blue-Chip Stocks Offering a Once-in-a-Lifetime Opportunity
If you're looking for a once-in-a-lifetime investment opportunity, consider these seven blue-chip stocks to buy now. 
Via InvestorPlace
Important Data Ahead, Tesla Turning On Massive Nvidia Cluster, 10 Drugs Name For Price Cuts
To gain an edge, this is what you need to know today. 
Via Benzinga
Nearing Retirement? These Stocks Will Pay You For Life
These companies are passive income machines. 
Via The Motley Fool
Blockbusters From AbbVie, Merck, Lilly Highlight List Of 10 Drugs Subject To Price Cuts
The Biden administration is planning to negotiate the prices of 10 drugs in 2026. 
Via Investor's Business Daily
As America Grapples With A Deadly Opioid Epidemic, BioRestorative Therapies Is Looking To Treat Chronic Pain Without The Need For Class-A Drugs
Chronic back pain is a significant issue in the United States, affecting millions of individuals annually. According to experts, up to 80% of the population will experience back pain at some point. 
Via Benzinga
7 Stocks to Buy for the Rest of 2023
With the stock market off to a bombastic start, these top stocks for 2023 are worth betting on for the remainder of the year 
Via InvestorPlace
Late-Summer Steals: 7 Stocks to Buy Before Fall
With the summer season coming to an end and investors returning from vacation, it’s time to consider these stocks to buy now. 
Via InvestorPlace
3 Surprisingly Underrated Stocks to Buy Right Now
These stocks deserve more respect than they're getting. 
Via The Motley Fool
Boeing's 737 Deliveries Delay Due To Supplier Spirit Aerosystems, Petco Health and Wellness Stock Tumbles, AstraZeneca Under Legal Lens: Today's Top Stories
Benzinga 
Via Benzinga
Topics Supply Chain
Exposures Boeing 737 Supply Chain
Cheaper Version Of Blockbuster Arthritis Treatment Humira - CVS Health Teams With Sandoz
CVS Health Corp (NYSE: CVS) has launched Cordavis, a wholly-owned subsidiary, to work directly with manufacturers to commercialize and/or co-produce biosimilar  
Via Benzinga
7 Very Oversold High-Yield Stocks to Buy Right Now
For speculators wanting to gamble the conservative way, these oversold high-yield stocks to buy may be what you’re looking for. 
Via InvestorPlace
7 Top Dividend Stocks for Income and Stability
With strong fundamentals and long track records of dividend growth, these are the top seven dividend stocks to buy. 
Via InvestorPlace
Large Cap Biopharmaceuticals Performance 2023 YTD: Mixed Results But Lilly Is A Big Winner
Biotech stocks are in a bear market since the IBB hit $177.37 in 2021 and is down 7.84% over five years. 
Via Talk Markets
Trillion-Dollar Trio: These 3 Super Growth Stocks Will Dominate the Market by 2035
As companies naturally continue to expand and the stock market grows, trillion-dollar valuations will be a more common occurrence. 
Via InvestorPlace
7 Blue-Chip Stocks Smart Investors Should Be Loading Up on Now
These shares of blue-chip stocks to buy continue to be attractive for smart investors who value strong firms and steady performance. 
Via InvestorPlace
7 Dividend Stocks to Buy as Investor Sentiment Falters
With economic uncertainty rising, investors can ride out the potential storm with these dividend stocks to buy. 
Via InvestorPlace
How Revance Is Taking A Page Out Of AbbVie's Botox Playbook
The company sells a cosmetic treatment. Now, it's bridging into neuroscience. 
Via Investor's Business Daily
My Top Dividend King to Buy and Hold for the Next 10 Years, and It Isn't Even Close
This stock offers a high dividend yield, impressive dividend growth, and a lot more. 
Via The Motley Fool
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
74 75 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.